Datar Cancer Genetics and Cromwell Hospital’s Second Opinion Service
Date – Oct. 17, 2023
Cromwell Hospital, a world-leading private hospital in London, is working with Datar Cancer Genetics as a trusted second opinion partner.
Sir Ian Botham: I’ve never been in the dressing room with any form of racism
Date – Aug. 10, 2023
Lord Ian Botham talks not just about racism but also the value of early cancer detection as he recently took the multi-cancer detection solution Trucheck.
US FDA Grants Breakthrough Designation for Blood Test to Help Diagnose Inaccessible Brain Tumors
Date – Jan. 2, 2023
Datar Cancer Genetics now has three Breakthrough Designations granted by the USFDA, including liquid biopsies for breast and prostate cancer detection.
Blood test which spots ‘nearly every case of cancer’ before it spreads, will improve early treatment
Date – Oct. 28, 2022
The Trucheck blood test can identify 70 types of cancer, with the company hoping it can be rolled out across the NHS
'Game Changer' Blood Test Detects Breast Cancer
Date – July 24, 2022
‘Game-changer’ blood test detects breast cancer earlier than X-rays, study shows.
Landmark Liquid Biopsy Study
Date – July 13, 2022
Landmark Liquid Biopsy Study Shows Accurate Detection of Early-Stage Breast Cancer.
The London Clinic
Date – April 11, 2022
Datar Cancer Genetics enters into partnership with The London Clinic to offer enhanced cancer testing services
FDA - Prostate Cancer
Date – February 14, 2022
Datar’s TriNetra-Prostate Blood Test Gets FDA Breakthrough Designation.
Date – February 2, 2022
Groundbreaking high-sensitivity cancer screening test arriving in SA ahead of World Cancer Day.
Date – December 7, 2021
Virtus Group announces partnership with Datar Cancer Genetics for personalized precision oncology solutions in Kuwait.
FDA - Breast Cancer
Date – November 19, 2021
US FDA Grants Breakthrough Designation for Early-Stage Breast Cancer Detection Blood Test Developed by Datar Cancer Genetics.
The Healthcare Technology Report
Date – October 19, 2021
The Top 25 Women Leaders in Biotechnology of 2021 (Swati Deshpande – Datar Cancer Genetics)
NICE - UK
Date – July 13, 2021
UK – National Institute for Health and Care Excellence (NICE) issues MedTech Innovation Briefing on ‘Trublood-Prostate’ for Precision Non-Invasive Prostate Cancer Diagnosis Described by Experts as a ‘Game Changer’.